Cookies
We use some essential cookies to make our service work.
We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site. Let us know if this is OK. We’ll use a cookie to save your choice and you can read more about your choices in our cookie policy.
Obesity Medication Pathway
Following a NICE Technology Approval publication (TA1026)
on 23 December 2024, tirzepatide (Mounjaro®) was recommended for use in Primary Care as a
new setting of care, for managing obesity, alongside a reduced-calorie diet and increased
physical activity in adults. There is an established eligibility criteria.
This standardised Integrated Patient Review Template has been rolled out on a national
scale in England for all GP practices through NHS England’s GPIT Providers. It will support
in the capture of essential data related to the NICE Funding Variation for the implementation
of prescribing of tirzepatide (Mounjaro®) for the management of obesity.
This is not a clinical management template. This is to confirm assessment of the patient
under the NHS Priority Cohorts under the
NICE Funding Variation for tirzepatide (Mounjaro®)
for the management of obesity in primary care. It is the prescriber’s responsibility
to review the BNF cautions, medication interactions, SmPC and local criteria.